The largest database of trusted experimental protocols

8 protocols using lna inhibitor

1

miR-21 Modulation in Human Islets

Check if the same lab product or an alternative is used in the 5 most similar protocols
INS-1 832/13 and 828/33 cells were seeded into a 12-well plate at a density of 4×105 cells/well and treated for 48 h with miR-21 5p (accession no. MI0000569) mimic used at a concentration of 45 pmol (Qiagen, Düsseldorf, Germany), or 100 pmol locked nucleic acid (LNA) inhibitor (Exiqon, Vedbaek, Denmark), or negative controls (Qiagen, Exiqon) that had been complexed with 3 μl Lipofectamine 3000 and 100 μl Opti-MEM (both from Thermo Fisher, Grand Island, NY, USA). Relative miR-21 expression after transfection is shown in the electronic supplementary material [ESM] Fig. 1.
For human islet dispersion and transfection, after 4 h of routine incubation at 37°C, islets were suspended in 4 ml of Accutase solution (Millipore, Billerica, MA, USA) with 100 units of DNase I (Millipore) in a thermal mixer at 37°C, 1000 rev/min for 10 min, followed by the addition of 10 ml of culture medium. Dispersed cells were collected by centrifugation at 200 g for 3 min, and then resuspended in culture medium and seeded into 12-well tissue culture plates (Falcon, Tewksbury, MA, USA). Dispersed cells from 200 islets were transfected with 23 pmol of either negative control miRNA or miR-21 mimic using Lipofectamine 3000 reagent as described above. Cleaved caspase 3 ELISA (ThermoFisher) was performed on transfected human islets as per the manufacturer’s protocol.
+ Open protocol
+ Expand
2

Intracerebroventricular Injection of miR-709 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male C57BL6/J mice were implanted with a 5-mm-long cannula (PlasticsOne) reaching the right ventricle at 0.3 mm posterior from the bregma (AP), 0.84 mm lateral from the midline (ML), and 2.43 mm depth (DV). After habituation to the implants and the recording room, mice were injected ICV by means of a Hamilton 5-μL syringe, with either LNA miR-709 specific power inhibitors (i-miR-709: 5′-CTC CTG CCT CTG CCT C-3′, Exiqon; 100 mM final conc., n = 7), LNA scrambled power inhibitors (scr: 5′-ACG TCT ATA CGC CCA-3′, Exiqon; 100 mM final conc., n = 7) or vehicle (n = 6), at a speed of 0.6 μL/min. The vehicle for all injections was 4 μL of artificial cerebrospinal fluid (aCSF; composed of 150 mM Na, 3.0 mM K, 1.4 mM Ca, 0.8 mM Mg, 1.0 mM P; 155 mM Cl; pH 7.4). Post-injection, animals were left undisturbed for 48 h prior to baseline recordings, as recommended by the LNA inhibitor manufacturer (Exiqon, Vedbaek, Denmark).
+ Open protocol
+ Expand
3

Transfecting Human Lung Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human lung cancer cell lines, A549 and H1299, were obtained from the American Type Culture Collection (ATCC, LGC Standards). Cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (Sigma Aldrich, Saint Louis, MO, USA). Cells were transfected using mirVana miRNA mimics (Thermo Fisher Scientific, Waltham, MA, USA) or locked nucleic acid (LNA) inhibitor (Exiqon, Vedbæk, Denmark) (50 nM) according to the manufacturer’s instructions. pMDM2 was kindly provided by Scotlandi. p53 transfection was performed using p53 plasmid (Origene, Rockville, MD, USA) following the company’s protocol.
+ Open protocol
+ Expand
4

Regulation of miR-21 Targets in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
4 × 105 cells/well were treated for 48 h with 100 pmol of a miR-21 locked nucleic acid (LNA) inhibitor (Exiqon), or negative controls (Qiagen), or 1.25 μg of a Tgfb2 vector (OriGene) complexed with 3 μl Lipofectamine 3000 and 100 μl Opti-MEM (ThermoFisher). LNA-transfected cells were treated with 5 ng/ml IL-1β for 24 h. The inhibitor was validated by confirming the increase in expression levels of previously validated targets Bcl2 and Pdcd4 (Supplementary Figure 3).
+ Open protocol
+ Expand
5

Wnt5a 3'UTR Regulation by miR-15b-3p

Check if the same lab product or an alternative is used in the 5 most similar protocols
On day 1, HEK293 cells were plated in a 6-well plate at a density of 0.5 × 106 cells per well. The following day, the cells were transfected with 250 ng of pmirGLO Dual-Luciferase miRNA Target Expression Vector (E1330 from Promega) containing Wnt5a 3′-UTR sequence, together with miR-15b-3p mimics or miRNA mimic control (Genepharma) at a final concentration of 50 nM. LNA inhibitors (Exiqon) were used at a concentration of 20 nM. Experiments were performed in triplicate. Luciferase activity was measured 72 h post-transfection using the Dual-Luciferase Reporter Assay System (E1960 from Promega) according to the manufacturer’s protocol. Renilla luciferase activity was normalized with respect to firefly luciferase activity and the percentage inhibition was calculated.
+ Open protocol
+ Expand
6

Luciferase Assay for miRNA Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
H9 cells were transiently transfected 2 days post-plating (30% confluence) in 24-well cell culture plates. X-tremeGene siRNA transfection reagent (Roche, Nutley, NJ) 5 μL per well was used to co-transfect luciferase-3′UTR constructs and a constitutively active Renilla luciferase construct (Promega, Madison, WI) as a control for transfection efficiency. H9 cells were co-transfected with luciferase-3′UTR constructs, Renilla luciferase construct, and 100 nM Anti-miR miRNA inhibitors (Ambion) or 50 nM LNA inhibitors (Exiqon, Woburn, MA) using 6 μL X-tremeGene siRNA transfection reagent per well. 24 h post-transfection, cultures were either maintained in pluripotent conditions (mTeSR1 medium) or in differentiation conditions (RA medium) for 24 h. Cultures were harvested in 1X Reporter Lysis Buffer (Promega), according to the manufacturer’s instructions. All transfection experiments were performed at least 6 times, using n=3–4 for each experiment. Equal aliquots of cell lysate were used to determine luciferase activity (Dual Luciferase Assay System, Promega). To control for transfection efficiency, firefly luciferase activity was normalized to that of Renilla luciferase.
+ Open protocol
+ Expand
7

Protein Analysis of Primary Mouse Neurons

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary mouse neurons, cultured as previous (Wei et al., 2017b (link)), were transfected with miRIDIAN miRNA mimics (25nM; Dharmacon) or LNA inhibitors (50nM; Exiqon), using Lipofectamine 2000. Total protein was isolated 24 hr later using RIPA buffer. Protein concentrations were determined using the bicinchoninic acid (BCA) assay. SDS-PAGE and immunoblot were performed as previous (Zhang et al., 2017 (link)). Briefly, equal amounts of proteins were resolved via 12% SDS-PAGE and transferred to 0.45 um PVDF membranes. After blocking with 5% BSA, membranes were incubated with 1:1000 diluted primary antibodies (Hdac3 (Santa Cruz Biotechnology, #sc-376957); β-actin (Beyotime Biotechnology, #AA128)), followed by HRP-conjugated secondary antibodies. The blots were developed by enhanced chemiluminescence (Beyotime) and quantified by ImageJ.
+ Open protocol
+ Expand
8

Investigating mTOR 3'UTR-miRNA interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wide-type and mutant-type of mTOR 3' untranslated regions (UTR) luciferase reporter vectors (50 ng) were constructed. Either 50 nM LNA inhibitors (Exiqon) or 50 nM pre-miRNAs (Ambion) were, along with the established wild/mutant-type luciferase reporter vectors, transfected into PC12 cells via Lipofectamine 2000 (Invitrogen). Luciferase activity was figured out with the Dual-Luciferase Reporter Assay System (Promega) when transfection lasted for at least 48 h. We also constructed reported vectors where miRNA-183 seed regions were mutated by virtue of Quick Change II XL Site Directed Mutagenesis Kit (Agilent).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!